Trial Profile
A Phase IIa Dose-Refinement Study of the Safety and Immunogenicity of a 3-Dose Regimen of the Merck Adenovirus Serotype 5 HIV-1 Gag/Pol/Nef Vaccine in Healthy Adults
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs V 520 (Primary)
- Indications HIV infections
- Focus Pharmacodynamics
- Sponsors Merck & Co; Merck Sharp & Dohme Corp.
- 22 Sep 2007 Status changed from recruiting to discontinued.
- 09 Jan 2007 Status change
- 27 Oct 2006 New trial record.